Copyright
©The Author(s) 2026.
World J Gastroenterol. Feb 14, 2026; 32(6): 115556
Published online Feb 14, 2026. doi: 10.3748/wjg.v32.i6.115556
Published online Feb 14, 2026. doi: 10.3748/wjg.v32.i6.115556
Figure 1 Flow chart illustrating decision about different treatment.
AC: Adjuvant chemotherapy; HIPEC: Hyperthermic intraperitoneal chemotherapy; pT4: Pathological T staging.
Figure 2 Overall survival, disease-free survival, disease-free interval, and peritoneal metastases-free interval in the hyperthermic intraperitoneal chemotherapy + adjuvant chemotherapy and adjuvant chemotherapy groups after propensity score matching.
A: Overall survival; B: Disease-free survival; C: Disease-free interval; D: Peritoneal metastases-free interval. AC: Adjuvant chemotherapy; HIPEC: Hyperthermic intraperitoneal chemotherapy; HR: Hazard ratio.
Figure 3 Patterns of recurrence and metastasis after propensity score matching.
A: Hyperthermic intraperitoneal chemotherapy + adjuvant chemotherapy group; B: Adjuvant chemotherapy group. AC: Adjuvant chemotherapy; HIPEC: Hyperthermic intraperitoneal chemotherapy.
- Citation: Lian WL, Cai LS, Lian MQ, Lian MJ, Sun YQ, Lv CB, Huang GP, Huang RJ, Zhang YB, Zeng WM, Xu QH, Zhu QJ, Chen QX. Efficacy and safety of sequential hyperthermic intraperitoneal chemotherapy following surgery for pathological T staging 4 gastric cancer. World J Gastroenterol 2026; 32(6): 115556
- URL: https://www.wjgnet.com/1007-9327/full/v32/i6/115556.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i6.115556